Market cap
$10.1bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
In connection with the IRAK4 program, we remain eligible to receive up to an additional $955 million in development and commercial milestones upon the achievement of certain developmental or regulatory events and upon the achievement of certain net sales thresholds. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. All of the revenue recognized for the three months ended June 30, 2026 is attributable to payments achieved under our collaboration agreements with Gilead and Sanofi. …Kymera Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05